Literature DB >> 21602699

CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.

Xiuhong Li1, Joseph B Margolick, Beth D Jamieson, Charles R Rinaldo, John P Phair, Lisa P Jacobson.   

Abstract

BACKGROUND: The heterogeneity of CD4 T-cell counts and HIV-1 RNA at 5-12 years after the initiation of highly active antiretroviral therapy (HAART) remains largely uncharacterized.
METHODS: In the Multicenter AIDS Cohort Study, 614 men who initiated HAART contributed data 5-12 years subsequently. Multivariate regression was used to evaluate the predictors of CD4 counts and HIV-1 RNA levels.
RESULTS: At 5 to 12 years post-HAART, the median CD4 T-cell count was 586 (interquartile range, 421-791) cells per microliter and 78% of the HIV-1 RNA measurements were undetectable. Higher CD4 T-cell counts 5-12 years post HAART were predicted by higher CD4 T-cell counts and higher total lymphocyte count pre HAART, lack of hepatitis B or C virus coinfections, and greater CD4 T-cell change and suppressed HIV-1 RNA in the first 5 years after starting HAART. Men who were 50 years and older with 351-500 CD4 cells per microliter at HAART initiation had adjusted mean CD4 T-cell count of 643 cells per microliter at 10-12 years post HAART, which was similar to the adjusted mean CD4 T-cell count (670 cells/μL, P = 0.45) in this period for younger men starting HAART with lower CD4 T-cell counts. HIV-1 RNA suppression in the first 5 years post HAART predicted subsequent viral suppression.
CONCLUSIONS: Immunological and virological responses in the first 5 years post HAART predicted subsequent CD4 T-cell counts and HIV-1 RNA levels. The association between age and subsequent CD4 T-cell count supports incorporating age in the guidelines for use of HAART.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21602699      PMCID: PMC3293185          DOI: 10.1097/QAI.0b013e31821e9f21

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  47 in total

1.  Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy.

Authors:  P M Tarwater; J B Margolick; J Jin; J P Phair; R Detels; C Rinaldo; J Giorgi; A Muñoz
Journal:  J Acquir Immune Defic Syndr       Date:  2001-06-01       Impact factor: 3.731

2.  Demographic characteristics and survival with AIDS: health disparities in Chicago, 1993-2001.

Authors:  Girma Woldemichael; Demian Christiansen; Sandra Thomas; Nanette Benbow
Journal:  Am J Public Health       Date:  2009-02-12       Impact factor: 9.308

3.  Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.

Authors:  Gilbert R Kaufmann; Hansjakob Furrer; Bruno Ledergerber; Luc Perrin; Milos Opravil; Pietro Vernazza; Matthias Cavassini; Enos Bernasconi; Martin Rickenbach; Bernard Hirschel; Manuel Battegay
Journal:  Clin Infect Dis       Date:  2005-06-24       Impact factor: 9.079

Review 4.  Nutrients and HIV: part two--vitamins A and E, zinc, B-vitamins, and magnesium.

Authors:  L Patrick
Journal:  Altern Med Rev       Date:  2000-02

5.  Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study.

Authors:  C A Kleeberger; J P Phair; S A Strathdee; R Detels; L Kingsley; L P Jacobson
Journal:  J Acquir Immune Defic Syndr       Date:  2001-01-01       Impact factor: 3.731

6.  Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV.

Authors:  Sophie Grabar; Isabelle Kousignian; Alain Sobel; Philippe Le Bras; Jacques Gasnault; Patricia Enel; Corinne Jung; Aba Mahamat; Jean-Marie Lang; Dominique Costagliola
Journal:  AIDS       Date:  2004-10-21       Impact factor: 4.177

7.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Authors:  Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

8.  Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.

Authors:  Jean-Jacques Parienti; Véronique Massari; Diane Descamps; Astrid Vabret; Elisabeth Bouvet; Bernard Larouzé; Renaud Verdon
Journal:  Clin Infect Dis       Date:  2004-04-14       Impact factor: 9.079

9.  Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.

Authors:  B T Røge; T S Barfod; O Kirk; T L Katzenstein; N Obel; H Nielsen; C Pedersen; L R Mathiesen; J D Lundgren; J Gerstoft
Journal:  HIV Med       Date:  2004-09       Impact factor: 3.180

10.  The Multicenter AIDS Cohort Study: retention after 9 1/2 years.

Authors:  J Dudley; S Jin; D Hoover; S Metz; R Thackeray; J Chmiel
Journal:  Am J Epidemiol       Date:  1995-08-01       Impact factor: 4.897

View more
  8 in total

Review 1.  Immunosenescence and hurdles in the clinical management of older HIV-patients.

Authors:  Marco Ripa; Stefania Chiappetta; Giuseppe Tambussi
Journal:  Virulence       Date:  2017-02-21       Impact factor: 5.882

2.  Prospective prediction of viral suppression and immune response nine months after ART initiation in Seattle, WA.

Authors:  Jane M Simoni; Samantha S Yard; David Huh
Journal:  AIDS Care       Date:  2012-05-29

3.  Ageing and long-term CD4 cell count trends in HIV-positive patients with 5 years or more combination antiretroviral therapy experience.

Authors:  S T Wright; K Petoumenos; M Boyd; A Carr; S Downing; C C O'Connor; M Grotowski; M G Law
Journal:  HIV Med       Date:  2012-10-04       Impact factor: 3.180

4.  Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy.

Authors:  Hamish McManus; Catherine C O'Connor; Mark Boyd; Jennifer Broom; Darren Russell; Kerrie Watson; Norman Roth; Phillip J Read; Kathy Petoumenos; Matthew G Law
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

5.  Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial.

Authors:  Pablo F Belaunzarán-Zamudio; Livio Azzoni; David H Canaday; Yanink N Caro-Vega; Brian Clagett; Mohammed S Rassool; Benigno Rodriguez; Ian Sanne; Irini Sereti; Juan G Sierra-Madero; Michael M Lederman
Journal:  Pathog Immun       Date:  2017-05-09

6.  Correlation between Lymphocyte CD4 Count, Treatment Duration, Opportunistic Infection and Cognitive Function in Human Immunodeficiency Virus-Acquired Immunodeficiency Syndrome (HIV-AIDS) Patients.

Authors:  Fasihah Irfani Fitri; Aldy Safruddin Rambe; Aida Fitri
Journal:  Open Access Maced J Med Sci       Date:  2018-04-13

7.  Characteristics and treatment outcomes of HIV infected elderly patients enrolled in Kisii Teaching and Referral Hospital, Kenya.

Authors:  Benuel Nyagaka; Stanslaus Kiilu Musyoki; Lucy Karani; Anthony Kebira Nyamache
Journal:  Afr Health Sci       Date:  2020-12       Impact factor: 0.927

8.  The effect of age on CD4+ T-cell recovery in HIV-suppressed adult participants: a sub-study from AIDS Clinical Trial Group (ACTG) A5321 and the Bone Loss and Immune Reconstitution (BLIR) study.

Authors:  Jingxian Chen; Kehmia Titanji; Anandi N Sheth; Rajesh Gandhi; Deborah McMahon; Ighovwerha Ofotokun; M Neale Weitzmann; Kristina De Paris; Julie B Dumond
Journal:  Immun Ageing       Date:  2022-01-03       Impact factor: 6.400

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.